Hansoh Pharmaceutical Group Company Limited Announces Licensing Agreement with Tiumbio Co., Ltd

The board of directors of Hansoh Pharmaceutical Group Company Limited announced that on August 8, 2022, Hansoh (Shanghai) Healthtech Company Ltd. and Jiangsu Hansoh Pharmaceutical Group Company Ltd., both wholly-owned subsidiaries of the Company, entered into an exclusive license and collaboration agreement (the "Licensing Agreement") with TiumBio Co., Ltd. ("TiumBio"). Pursuant to the Licensing Agreement, the Licensees obtained an exclusive license from TiumBio to develop and commercialize TU2670 for the treatment of endometriosis, uterine fibroids and other indications within China (including Hong Kong, Macau and Taiwan). The Licensees will be responsible for the development, regulatory approval and commercialization of TU2670 in China, and will pay a US$4.5 million upfront payment, a US$1.5 million technology transfer payment and potential payments upon reaching development, regulatory and sales-based commercial milestones of up to US$164 million, plus tiered royalties on future net product sales. TU2670 is an orally active non-peptide GnRH antagonist. Early phase clinical trials have demonstrated excellent safety and tolerability of TU2670.

SOURCE Hansoh Pharmaceutical